Carregant...
Benzimidazole-based FabI inhibitors: A promising novel scaffold for anti-staphylococcal drug development
The enoyl-ACP reductase (FabI) enzyme is a well validated target for anti-staphylococcal drug discovery and development. With the goal of finding alternate therapeutics for drug resistant strains of S. aureus, such as methicillin resistant S. aureus (MRSA), our previously published series of benzimi...
Guardat en:
| Publicat a: | ACS Infect Dis |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5659837/ https://ncbi.nlm.nih.gov/pubmed/27756129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.6b00123 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|